1、 KOBAYASHI T,SIEGMUND B,LE BERRE C,et al.Ulcerative colitis[J].Nature Reviews Disease Primers,2020,6(1):74. KOBAYASHI T,SIEGMUND B,LE BERRE C,et al.Ulcerative colitis[J].Nature Reviews Disease Primers,2020,6(1):74.
2、 SAEZ A,HERRERO-FERNANDEZ B,GOMEZ-BRIS R,et al.Pathophysiology of Inflammatory Bowel Disease:Innate Immune System[J].International Journal of Molecular Sciences,2023,24(2):1526. SAEZ A,HERRERO-FERNANDEZ B,GOMEZ-BRIS R,et al.Pathophysiology of Inflammatory Bowel Disease:Innate Immune System[J].International Journal of Molecular Sciences,2023,24(2):1526.
3、 MONTAIGNE D,BUTRUILLE L,STAELS B.PPAR control of metabolism and cardiovascular functions[J].Nature Reviews Cardiology,2021,18(12):809-823. MONTAIGNE D,BUTRUILLE L,STAELS B.PPAR control of metabolism and cardiovascular functions[J].Nature Reviews Cardiology,2021,18(12):809-823.
4、 CAIONI G,VISCIDO A,D’ANGELO M,et al.Inflammatory Bowel Disease:New Insights into the Interplay between Environmental Factors and PPARγ[J].International Journal of Molecular Sciences,2021,22(3):985. CAIONI G,VISCIDO A,D’ANGELO M,et al.Inflammatory Bowel Disease:New Insights into the Interplay between Environmental Factors and PPARγ[J].International Journal of Molecular Sciences,2021,22(3):985.
5、 NG S C,SHI H Y,HAMIDI N,et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:A systematic review of population-based studies[J].The Lancet,2017,390(10114):2769-2778. NG S C,SHI H Y,HAMIDI N,et al.Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century:A systematic review of population-based studies[J].The Lancet,2017,390(10114):2769-2778.
6、 BUIE M J,QUAN J,WINDSOR J W,et al.Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century:A Systematic Review With Temporal Analyses[J].Clinical Gastroenterology and Hepatology,2023,21(9):2211-2221. BUIE M J,QUAN J,WINDSOR J W,et al.Global Hospitalization Trends for Crohn’s Disease and Ulcerative Colitis in the 21st Century:A Systematic Review With Temporal Analyses[J].Clinical Gastroenterology and Hepatology,2023,21(9):2211-2221.
7、 AGRAWAL M,ALLIN K H,PETRALIA F,et al.Multiomics to elucidate inflammatory bowel disease risk factors and pathways[J].Nature Reviews Gastroenterology & Hepatology,2022,19(6):399-409. AGRAWAL M,ALLIN K H,PETRALIA F,et al.Multiomics to elucidate inflammatory bowel disease risk factors and pathways[J].Nature Reviews Gastroenterology & Hepatology,2022,19(6):399-409.
8、 SHAN Y,LEE M,CHANG E B.The gut microbiome and inflammatory bowel diseases[J].Annual Review of Medicine,2022,73:455-468. SHAN Y,LEE M,CHANG E B.The gut microbiome and inflammatory bowel diseases[J].Annual Review of Medicine,2022,73:455-468.
9、 OHKUSA T.Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis[J].Gut,2003,52(1):79-83. OHKUSA T.Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis[J].Gut,2003,52(1):79-83.
10、 SCHAUBECK M,CLAVEL T,CALASAN J,et al.Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence[J].Gut,2016,65(2):225-237. SCHAUBECK M,CLAVEL T,CALASAN J,et al.Dysbiotic gut microbiota causes transmissible Crohn’s disease-like ileitis independent of failure in antimicrobial defence[J].Gut,2016,65(2):225-237.
11、 YANG Y,ZHENG X,WANG Y,et al.Human fecal microbiota transplantation reduces the susceptibility to dextran sulfate sodium-induced germ-free mouse colitis[J].Frontiers in Immunology,2022,13:836542. YANG Y,ZHENG X,WANG Y,et al.Human fecal microbiota transplantation reduces the susceptibility to dextran sulfate sodium-induced germ-free mouse colitis[J].Frontiers in Immunology,2022,13:836542.
12、 SCHIRMER M,FRANZOSA E A,LLOYD-PRICE J,et al.Dynamics of metatranscription in the inflammatory bowel disease gut microbiome[J].Nature Microbiology,2018,3(3):337-346. SCHIRMER M,FRANZOSA E A,LLOYD-PRICE J,et al.Dynamics of metatranscription in the inflammatory bowel disease gut microbiome[J].Nature Microbiology,2018,3(3):337-346.
13、 LLEAL M,SARRABAYROUSE G,WILLAMIL J,et al.A single faecal microbiota transplantation modulates the microbiome and improves clinical manifestations in a rat model of colitis[J].EBioMedicine,2019,48:630-641. LLEAL M,SARRABAYROUSE G,WILLAMIL J,et al.A single faecal microbiota transplantation modulates the microbiome and improves clinical manifestations in a rat model of colitis[J].EBioMedicine,2019,48:630-641.
14、 FEIGE J N,GELMAN L,MICHALIK L,et al.From molecular action to physiological outputs:Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions[J].Progress in Lipid Research,2006,45(2):120-159. FEIGE J N,GELMAN L,MICHALIK L,et al.From molecular action to physiological outputs:Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions[J].Progress in Lipid Research,2006,45(2):120-159.
15、 DUBOIS V,EECKHOUTE J,LEFEBVRE P,et al.Distinct but complementary contributions of PPAR isotypes to energy homeostasis[J].Journal of Clinical Investigation,2017,127(4):1202-1214. DUBOIS V,EECKHOUTE J,LEFEBVRE P,et al.Distinct but complementary contributions of PPAR isotypes to energy homeostasis[J].Journal of Clinical Investigation,2017,127(4):1202-1214.
16、 HAN L,SHEN W J,BITTNER S,et al.PPARs:Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease.Part I:PPAR-α[J].Future Cardiology,2017,13(3):259-278. HAN L,SHEN W J,BITTNER S,et al.PPARs:Regulators of Metabolism and As Therapeutic Targets in Cardiovascular disease.Part I:PPAR-α[J].Future Cardiology,2017,13(3):259-278.
17、 MANSéN A,GUARDIOLA-DIAZ H,RAFTER J,et al.Expression of the peroxisome proliferator-activated receptor(PPAR)in the mouse colonic mucosa[J].Biochemical and Biophysical Research Communications,1996,222(3):844-851. MANSéN A,GUARDIOLA-DIAZ H,RAFTER J,et al.Expression of the peroxisome proliferator-activated receptor(PPAR)in the mouse colonic mucosa[J].Biochemical and Biophysical Research Communications,1996,222(3):844-851.
18、 CHEN H,TAN H,WAN J,et al.PPAR-γ signaling in nonalcoholic fatty liver disease:Pathogenesis and therapeutic targets[J].Pharmacology & Therapeutics,2023,245:108391. CHEN H,TAN H,WAN J,et al.PPAR-γ signaling in nonalcoholic fatty liver disease:Pathogenesis and therapeutic targets[J].Pharmacology & Therapeutics,2023,245:108391.
19、 WU L,LI J,FENG J,et al.Crosstalk between PPARs and gut microbiota in NAFLD[J].Biomedicine & Pharmacotherapy,2021,136:111255. WU L,LI J,FENG J,et al.Crosstalk between PPARs and gut microbiota in NAFLD[J].Biomedicine & Pharmacotherapy,2021,136:111255.
20、 DELERIVE P,DE BOSSCHER K,BESNARD S,et al.Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1[J].Journal of Biological Chemistry,1999,274(45):32048-32054. DELERIVE P,DE BOSSCHER K,BESNARD S,et al.Peroxisome proliferator-activated receptor α negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-κB and AP-1[J].Journal of Biological Chemistry,1999,274(45):32048-32054.
21、 CUZZOCREA S,DI PAOLA R,MAZZON E,et al.Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha(PPAR-α)in the development of inflammatory bowel disease in mice[J].Laboratory Investigation,2004,84(12):1643-1654. CUZZOCREA S,DI PAOLA R,MAZZON E,et al.Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha(PPAR-α)in the development of inflammatory bowel disease in mice[J].Laboratory Investigation,2004,84(12):1643-1654.
22、 CUZZOCREA S,BRUSCOLI S,MAZZON E,et al.Peroxisome proliferator-activated receptor-α contributes to the anti-Inflammatory activity of glucocorticoids[J].Molecular Pharmacology,2008,73(2):323-337. CUZZOCREA S,BRUSCOLI S,MAZZON E,et al.Peroxisome proliferator-activated receptor-α contributes to the anti-Inflammatory activity of glucocorticoids[J].Molecular Pharmacology,2008,73(2):323-337.
23、 HERRANZ-LóPEZ M,BARRAJóN-CATALáN E,SEGURA-CARRETERO A,et al.Lemon verbena(Lippia citriodora)polyphenols alleviate obesity-related disturbances in hypertrophic adipocytes through AMPK-dependent mechanisms[J].Phytomedicine,2015,22(6):605-614. HERRANZ-LóPEZ M,BARRAJóN-CATALáN E,SEGURA-CARRETERO A,et al.Lemon verbena(Lippia citriodora)polyphenols alleviate obesity-related disturbances in hypertrophic adipocytes through AMPK-dependent mechanisms[J].Phytomedicine,2015,22(6):605-614.
24、 YAMAMOTO-FURUSHO J K,JACINTEZ-CAZARES M,FURUZAWA-CARBALLEDA J,et al.Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis[J].Disease Markers,2014(2014):932530. YAMAMOTO-FURUSHO J K,JACINTEZ-CAZARES M,FURUZAWA-CARBALLEDA J,et al.Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis[J].Disease Markers,2014(2014):932530.
25、 MAZZON E,CUZZOCREA S.Absence of functional peroxisome proliferator-activated receptor-alpha enhanced ileum permeability during experimental colitis[J].Shock,2007,28(2):192-201. MAZZON E,CUZZOCREA S.Absence of functional peroxisome proliferator-activated receptor-alpha enhanced ileum permeability during experimental colitis[J].Shock,2007,28(2):192-201.
26、 GRYGIEL-GóRNIAK B.Peroxisome proliferator-activated receptors and their ligands:nutritional and clinical implications - a review[J].Nutrition Journal,2014,13:17. GRYGIEL-GóRNIAK B.Peroxisome proliferator-activated receptors and their ligands:nutritional and clinical implications - a review[J].Nutrition Journal,2014,13:17.
27、 WAGNER N,WAGNER K D.Pharmacological utility of PPAR modulation for angiogenesis in cardiovascular disease[J].International Journal of Molecular Sciences,2023,24(3):2345. WAGNER N,WAGNER K D.Pharmacological utility of PPAR modulation for angiogenesis in cardiovascular disease[J].International Journal of Molecular Sciences,2023,24(3):2345.
28、 TORAL M,GóMEZ-GUZMáN M,JIMéNEZ R,et al.Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension,vascular inflammatory and oxidative status,and endothelial dysfunction in diet-induced obesity[J].Journal of Hypertension,2015,33(9):1831-1844. TORAL M,GóMEZ-GUZMáN M,JIMéNEZ R,et al.Chronic peroxisome proliferator-activated receptorβ/δ agonist GW0742 prevents hypertension,vascular inflammatory and oxidative status,and endothelial dysfunction in diet-induced obesity[J].Journal of Hypertension,2015,33(9):1831-1844.
29、 SHAN W,NICOL C J,ITO S,et al.Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice[J].Hepatology,2008,47(1):225-235. SHAN W,NICOL C J,ITO S,et al.Peroxisome proliferator-activated receptor-β/δ protects against chemically induced liver toxicity in mice[J].Hepatology,2008,47(1):225-235.
30、 BOUGUEN G,LANGLOIS A,DJOUINA M,et al.Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during ulcerative colitis[J].Gut,2015,64(6):901-910. BOUGUEN G,LANGLOIS A,DJOUINA M,et al.Intestinal steroidogenesis controls PPARγ expression in the colon and is impaired during ulcerative colitis[J].Gut,2015,64(6):901-910.
31、 BASSAGANYA-RIERA J,REYNOLDS K,MARTINO-CATT S,et al.Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease[J].Gastroenterology,2004,127(3):777-791. BASSAGANYA-RIERA J,REYNOLDS K,MARTINO-CATT S,et al.Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease[J].Gastroenterology,2004,127(3):777-791.
32、 CHOO J,LEE Y,YAN X JIA,et al.A novel peroxisome proliferator-activated receptor(PPAR)γ agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate exerts anti-inflammatory effects in colitis[J].Journal of Biological Chemistry,2015,290(42):25609-25619. CHOO J,LEE Y,YAN X JIA,et al.A novel peroxisome proliferator-activated receptor(PPAR)γ agonist 2-Hydroxyethyl 5-chloro-4,5-didehydrojasmonate exerts anti-inflammatory effects in colitis[J].Journal of Biological Chemistry,2015,290(42):25609-25619.
33、 SHEN P,ZHANG Z,HE Y,et al.Magnolol treatment attenuates dextran sulphate sodium-induced murine experimental colitis by regulating inflammation and mucosal damage[J].Life Sciences,2018(196):69-76. SHEN P,ZHANG Z,HE Y,et al.Magnolol treatment attenuates dextran sulphate sodium-induced murine experimental colitis by regulating inflammation and mucosal damage[J].Life Sciences,2018(196):69-76.
34、 KONG R,LUO H,WANG N,et al.Portulaca extract attenuates development of dextran sulfate sodium induced colitis in mice through activation of PPAR γ[J].PPAR Research,2018(2018):6079101. KONG R,LUO H,WANG N,et al.Portulaca extract attenuates development of dextran sulfate sodium induced colitis in mice through activation of PPAR γ[J].PPAR Research,2018(2018):6079101.
35、 NAKAJIMA A,WADA K,MIKI H,et al.Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury[J].Gastroenterology,2001,120(2):460-469. NAKAJIMA A,WADA K,MIKI H,et al.Endogenous PPARγ mediates anti-inflammatory activity in murine ischemia-reperfusion injury[J].Gastroenterology,2001,120(2):460-469.
36、 LINARD C,GRéMY O,BENDERITTER M.Reduction of peroxisome proliferation-activated receptor γ expression by γ-Irradiation as a mechanism contributing to inflammatory response in rat colon:Modulation by the 5-Aminosalicylic acid agonist[J].Journal of Pharmacology and Experimental Therapeutics,2008,324(3):911-920. LINARD C,GRéMY O,BENDERITTER M.Reduction of peroxisome proliferation-activated receptor γ expression by γ-Irradiation as a mechanism contributing to inflammatory response in rat colon:Modulation by the 5-Aminosalicylic acid agonist[J].Journal of Pharmacology and Experimental Therapeutics,2008,324(3):911-920.
37、 RAMAKERS J D,VERSTEGE M I,THUIJLS G,et al.The PPARγ agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis[J].Journal of Clinical Immunology,2007,27(3):275-283. RAMAKERS J D,VERSTEGE M I,THUIJLS G,et al.The PPARγ agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis[J].Journal of Clinical Immunology,2007,27(3):275-283.
38、 DESREUMAUX P,DUBUQUOY L,NUTTEN S,et al.Attenuation of colon inflammation through activators of the retinoid X receptor(Rxr)/peroxisome proliferator-activated receptor γ(pparγ)heterodimer[J].The Journal of Experimental Medicine,2001,193(7):827-838. DESREUMAUX P,DUBUQUOY L,NUTTEN S,et al.Attenuation of colon inflammation through activators of the retinoid X receptor(Rxr)/peroxisome proliferator-activated receptor γ(pparγ)heterodimer[J].The Journal of Experimental Medicine,2001,193(7):827-838.
39、 ONUKI M,WATANABE M,ISHIHARA N,et al.A partial agonist for retinoid X receptor mitigates ONUKI M,WATANABE M,ISHIHARA N,et al.A partial agonist for retinoid X receptor mitigates
40、experimental colitis[J].International Immunology,2019,31(4):251-262.experimental colitis[J].International Immunology,2019,31(4):251-262.
41、[40] DING Y,BU X,ZHANG N,et al.Effects of metabolizable energy and crude protein levels on laying performance,egg quality and serum biochemical indices of Fengda-1 layers[J].Animal Nutrition,2016,2(2):93-98.[40] DING Y,BU X,ZHANG N,et al.Effects of metabolizable energy and crude protein levels on laying performance,egg quality and serum biochemical indices of Fengda-1 layers[J].Animal Nutrition,2016,2(2):93-98.
42、[41] ARE A,ARONSSON L,WANG S,et al.Enterococcus faecalis from newborn babies regulate endogenous PPARγ activity and IL-10 levels in colonic epithelial cells[J].Proceedings of the National Academy of Sciences,2008,105(6):1943-1948.[41] ARE A,ARONSSON L,WANG S,et al.Enterococcus faecalis from newborn babies regulate endogenous PPARγ activity and IL-10 levels in colonic epithelial cells[J].Proceedings of the National Academy of Sciences,2008,105(6):1943-1948.
43、[42] KUNDU P,LING T W,KORECKA A,et al.Absence of intestinal PPARγ aggravates acute infectious colitis in mice through a lipocalin-2-dependent pathway[J].PLoS Pathogens,2014,10(1):e1003887.[42] KUNDU P,LING T W,KORECKA A,et al.Absence of intestinal PPARγ aggravates acute infectious colitis in mice through a lipocalin-2-dependent pathway[J].PLoS Pathogens,2014,10(1):e1003887.
44、[43] WAGNERBERGER S,SPRUSS A,KANURI G,et al.Lactobacillus casei Shirota protects from fructose-induced liver steatosis:A mouse model[J].The Journal of Nutritional Biochemistry,2013,24(3):531-538.[43] WAGNERBERGER S,SPRUSS A,KANURI G,et al.Lactobacillus casei Shirota protects from fructose-induced liver steatosis:A mouse model[J].The Journal of Nutritional Biochemistry,2013,24(3):531-538.
45、[44] ANGELAKIS E,BASTELICA D,BEN AMARA A,et al.An evaluation of the effects of Lactobacillus ingluviei on body weight,the intestinal microbiome and metabolism in mice[J].Microbial Pathogenesis,2012,52(1):61-68.[44] ANGELAKIS E,BASTELICA D,BEN AMARA A,et al.An evaluation of the effects of Lactobacillus ingluviei on body weight,the intestinal microbiome and metabolism in mice[J].Microbial Pathogenesis,2012,52(1):61-68.
46、[45] SUN S S,WANG K,MA K,et al.An insoluble polysaccharide from the sclerotium of Poria cocos improves hyperglycemia,hyperlipidemia and hepatic steatosis in ob/ob mice via modulation of gut microbiota[J].Chinese Journal of Natural Medicines,2019,17(1):3-14.[45] SUN S S,WANG K,MA K,et al.An insoluble polysaccharide from the sclerotium of Poria cocos improves hyperglycemia,hyperlipidemia and hepatic steatosis in ob/ob mice via modulation of gut microbiota[J].Chinese Journal of Natural Medicines,2019,17(1):3-14.
47、[46] OH H Y P,VISVALINGAM V,WAHLI W.The PPAR-microbiota-metabolic organ trilogy to fine‐tune physiology[J].The FASEB Journal,2019,33(9):9706-9730.[46] OH H Y P,VISVALINGAM V,WAHLI W.The PPAR-microbiota-metabolic organ trilogy to fine‐tune physiology[J].The FASEB Journal,2019,33(9):9706-9730.
48、[47] ZHANG K,MENG M,GAO L,et al.Sodium butyrate improves high-concentrate-diet-induced impairment of ruminal epithelium barrier function in goats[J].Journal of Agricultural and Food Chemistry,2018,66(33):8729-8736.[47] ZHANG K,MENG M,GAO L,et al.Sodium butyrate improves high-concentrate-diet-induced impairment of ruminal epithelium barrier function in goats[J].Journal of Agricultural and Food Chemistry,2018,66(33):8729-8736.
49、[48] HONG Y H,NISHIMURA Y,HISHIKAWA D,et al.Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43[J].Endocrinology,2005,146(12):5092-5099.[48] HONG Y H,NISHIMURA Y,HISHIKAWA D,et al.Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43[J].Endocrinology,2005,146(12):5092-5099.
50、[49] ZHANG W,CHENG C,HAN Q,et al.Flos Abelmoschus manihot extract attenuates DSS-induced colitis by regulating gut microbiota and Th17/Treg balance[J].Biomedicine & Pharmacotherapy,2019(117):109162.[49] ZHANG W,CHENG C,HAN Q,et al.Flos Abelmoschus manihot extract attenuates DSS-induced colitis by regulating gut microbiota and Th17/Treg balance[J].Biomedicine & Pharmacotherapy,2019(117):109162.
51、[50] BYNDLOSS M X,OLSAN E E,RIVERA-CHáVEZ F,et al.Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion[J].Science,2017,357(6351):570-575.[50] BYNDLOSS M X,OLSAN E E,RIVERA-CHáVEZ F,et al.Microbiota-activated PPAR-γ signaling inhibits dysbiotic Enterobacteriaceae expansion[J].Science,2017,357(6351):570-575.
52、[51] MANOHARAN I,SURYAWANSHI A,HONG Y,et al.Homeostatic PPARα signaling limits inflammatory responses to commensal microbiota in the intestine[J].The Journal of Immunology,2016,196(11):4739-4749.[51] MANOHARAN I,SURYAWANSHI A,HONG Y,et al.Homeostatic PPARα signaling limits inflammatory responses to commensal microbiota in the intestine[J].The Journal of Immunology,2016,196(11):4739-4749.
53、[52] ZENEWICZ L A,YIN X,WANG G,et al.IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic[J].The Journal of Immunology,2013,190(10):5306-5312.[52] ZENEWICZ L A,YIN X,WANG G,et al.IL-22 deficiency alters colonic microbiota to be transmissible and colitogenic[J].The Journal of Immunology,2013,190(10):5306-5312.
54、[53] SHOU J W,SHAW P C.Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma[J].Phytomedicine,2023(115):154842.[53] SHOU J W,SHAW P C.Berberine activates PPARδ and promotes gut microbiota-derived butyric acid to suppress hepatocellular carcinoma[J].Phytomedicine,2023(115):154842.
